tacrolimus and pimonidazole

tacrolimus has been researched along with pimonidazole* in 1 studies

Other Studies

1 other study(ies) available for tacrolimus and pimonidazole

ArticleYear
Tacrolimus (FK506) limits accumulation of granulocytes and platelets and protects against brain damage after transient focal cerebral ischemia in rat.
    Biological & pharmaceutical bulletin, 2007, Volume: 30, Issue:2

    We investigated the neuroprotective effect of tacrolimus (FK506) on the ischemia-reperfusion injury caused by transient focal brain ischemia induced by middle cerebral artery (MCA) occlusion for 60 min in rats. Neuronal damage visualized as a decrease of MAP2 immunoreactivity was observed in the cerebral cortex at 9 h after MCA occlusion and further expanded at 24 h. Hypoxic areas visualized with an immunohistochemical reaction for 2-nitroimidazole, a hypoxia marker (hypoxyprobe-1), and accumulation of granulocytes and platelets were also observed at 9 h and 24 h after MCA occlusion. Tacrolimus (1 mg/kg, i.v.), administered immediately after MCA occlusion, attenuated cortical damage and decreased the hypoxyprobe-1 positive area, as well as the number of granulocytes and platelets at 24 h after MCA occlusion. Immunohistochemical analysis showed that tacrolimus reduced the number of blood vessels positively stained for ICAM-1, E-selectin and P-selection. These results suggested that tacrolimus limited attachment of granulocytes and platelets to blood vessels by inhibiting the expression of adhesion molecules and protected neuronal tissue from hypoxic insults.

    Topics: Animals; Blood Platelets; Brain Ischemia; Cell Adhesion; Cerebral Cortex; Granulocytes; Infarction, Middle Cerebral Artery; Intercellular Adhesion Molecule-1; Male; Microtubule-Associated Proteins; Neuroprotective Agents; Nitroimidazoles; Rats; Rats, Wistar; Tacrolimus

2007